MVAIF yields 2267.57% · JNJ yields 2.13%● Live data
📍 MVAIF pulled ahead of the other in Year 1
Combined, MVAIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MVAIF + JNJ for your $10,000?
Minerva Intelligence Inc., a software development company, provides proprietary AI software and related consulting services. Its principal products include DRIVER uses Machine Learning-based statistical models to automate and accelerate 3D modelling of drilling datasets; Language Extender and Organizer uses controlled vocabularies to automatically index and tag its files, making document management, and searchable, as well as a system for managing a corporation's digital knowledge assets; TARGET, a cognitive AI system that produces explainable exploration targets by mimicking the traditional process of geological data evaluation; SOLACE enables organizations to create and curate standards and design self-improving workflows to align current and future datasets. The company also offers Aristotelian Class Editor, a free software application developed to build taxonomies for use in artificial intelligence applications. In addition, it provides climate85 solutions to enhance the understanding of impacts of climate changes, to adapt and identify opportunities for various industries; and TERRA mining AI platform. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Full MVAIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.